Skip to main content
SpringerLink
Log in

Leishmanioses cutanées

  • Chapter
Manifestations dermatologiques des maladies infectieuses, métaboliques et toxiques

  • 683 Accesses

Abstrait

Les leishmanioses sont des maladies parasitaires causées par un protozoaire flagellé appartenant au genre Leishmania. Celui-ci comprend environ 30 espèces différentes qui, suivant leur tropisme pour la peau, les muqueuses de la face ou les organes profonds, sont responsables, chez l’homme, de différentes formes de maladies: leishmanioses cutanées (LC), cutanéo-muqueuses (LMC) ou leishmaniose viscérale (LV). Mais cette variabilité d’expression clinique ne résulte pas uniquement de la diversité des espèces de Leishmania et de leur tropisme, mais également de la réponse immunitaire de l’hôte.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Dedet JP, Pratlong F. Leishmaniasis. In: Cook GC, Zumla A, eds. Manson’s Tropical Diseases. 21st ed. London: Saunders Elsevier Science Limited; 2003. p. 1339–1371.

    Google Scholar 

  2. Desjeux P (1993). Global control and Leishmania HIV co-infection. Clin Dermatol 1999; 17:317–325.

    Article  Google Scholar 

  3. Lumsden WHR. Biochemical taxonomy of Leishmania. Trans Roy Soc Trop Med Hyg 1974; 68:74–75.

    Article  PubMed  CAS  Google Scholar 

  4. Gardener PJ, Chance ML, Peters W. Biochemical taxonomy of Leishmania. II. Electrophoretic variation of malate dehydrogenase. Ann Trop Med Parasitol 1974; 68:317–325.

    PubMed  CAS  Google Scholar 

  5. Rioux JA, Lanotte G, Serres E et al. Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification. Ann Parasit hum comp 1990; 65:111–125.

    CAS  Google Scholar 

  6. Walters LL. Leishmania differentiation in natural and unnatural sandfly hosts. J Eukaryot Microbiol 1993; 40:196–206.

    Article  PubMed  CAS  Google Scholar 

  7. Lainson R, Shaw JJ. The role of animals in the epidemiology of South American leishmaniasis. In Lumsden WHR, Evans DA, eds. Biology of the Kinetoplastida, vol. 2. London: Academic Press; 1979. p. 1–116.

    Google Scholar 

  8. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans Roy Soc Trop Med Hyg 2001; 95:239–243.

    Article  PubMed  CAS  Google Scholar 

  9. Dedet JP. Leishmania et leishmanioses du continent américain. Bull Inst Pasteur 1993; 4:3–25.

    Google Scholar 

  10. Pratlong F, Rioux JA, Marty P et al. Isoenzymatic analysis of 712 strains of Leishmania infantum in the South of France and relatioship of enzymatic polymorphism to clinical and epidemiological features. J Clin Microbiol 2004; 42:4077–4082.

    Article  PubMed  CAS  Google Scholar 

  11. Pratlong F, Bastien P, Perello P et al. Human cutaneous leishmaniasis caused by Leishmania donovani sensu stricto in Yemen. Trans Roy Soc Trop Med Hyg 1995; 89:398–399.

    Article  PubMed  CAS  Google Scholar 

  12. Pratlong F, Dedet JP, Marty P et al. Leishmania-human immunodeficiency virus coinfection in the Mediterranean Basin: isoenzymatic characterisation of 100 isolates of the Leishmania infantum complex. J Infect Dis 1995; 172:323–326.

    PubMed  CAS  Google Scholar 

  13. Pratlong F, Lambert M, Bastien P, Dedet JP. Leishmanioses et immunodépression. Aspects biocliniques actuels. Rev Franc Labor 1997; 291:161–168.

    Article  Google Scholar 

  14. Develoux M, Diallo S, Dieng Y et al. Diffuse cutaneous leishmaniasis due to Leishmania major in Sénégal. Trans R Soc trop Med Hyg 1996; 90:396–397.

    Article  PubMed  CAS  Google Scholar 

  15. Mahe A, Gessain A, Huerre M et al. Erythrodermic diffuse cutaneous leishmaniasis with Sezary syndrome. Lancet 1996; 348:405–406.

    Article  PubMed  CAS  Google Scholar 

  16. Solbach W, Laskay T. Leishmania major infection: the overture. Parasitol Today 1995; 11:394–397.

    Article  PubMed  CAS  Google Scholar 

  17. Locksley RM, Heinzel FP, Holaday BJ et al. Induction of Th1 and Th2 CD4+ subsets during murine L. major infection. Res Immunol 1991; 142:29–32.

    Google Scholar 

  18. Convit J, Ulrich M, Fernandez CT et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans Roy Soc Trop Med Hyg 1993; 87:444–448.

    Article  PubMed  CAS  Google Scholar 

  19. Barral-Netto M, Machado P, Barral A. Human cutaneous leishmaniasis: recent advances in physiopathology and treatment. Eur J Dermatol 1995; 5:104–113.

    Google Scholar 

  20. Ravisse P. Histopathologie de la leishmaniose. Bull Soc Path Exo 1978; 71:78–84.

    CAS  Google Scholar 

  21. Carvalho EM, Barral A, Costa JML et al. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Acta Trop 1994; 56:315–325.

    Article  PubMed  CAS  Google Scholar 

  22. Dedet JP, Esterre P, Pradinaud R. Individual clothing prophylaxis of cutaneous leishmaniasis in the Amazonian area. Trans Roy Soc Trop Med Hyg 1987; 81:748.

    Article  PubMed  CAS  Google Scholar 

  23. Convit J, Lapenta P. Sobre un caso de leishmaniasis tegumentaria de forma diseminada. Rev Policlin Caracas 1948; 17:153–158.

    Google Scholar 

  24. Dedet JP, Lambert M, Pratlong F. Leishmanioses et infection par le virus de l’immunodéficience humaine. Presse Med 1995; 24:1036–1040.

    PubMed  CAS  Google Scholar 

  25. Escomel E. La Espundia. Bull Soc Path Exot 1911; 4:489–492.

    Google Scholar 

  26. Marsden PD. Mucosal leishmaniasis (« espundia » Escomel, 1911). Trans Roy Soc Trop Med Hyg 1986; 80:859–876.

    Article  PubMed  CAS  Google Scholar 

  27. Villela F, Pestana BR, Pessoa SB. Presença de Leishmania braziliensis na mucosa nasal sem lesão aparente, en casos recentes de leishmaniase cutanea. Hospital 1939; 16:953.

    Google Scholar 

  28. Evans DA, Godfrey D, Lanham S et al. Handbook on isolation, characterization and cryopreservation of Leishmania. Geneva: WHO; 1989: 45 p.

    Google Scholar 

  29. Pratlong F, Martini A, Lambert M et al. Intérêt de la culture et de l’identification iso-enzymatique des Leishmanies dans le diagnostic et l’épidémiologie des leishmanioses. Med Armees 1994; 22:61–65.

    Google Scholar 

  30. Faraut-Gambarelli F, Piarroux R, Deniau M et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 1997; 41:827–830.

    PubMed  CAS  Google Scholar 

  31. Andresen K, Gaafar A, El-Hassan AM et al. Evaluation of the polymerase chain reaction in the diagnosis of cutaneous leishmaniasis due to Leishmania major: a comparison with direct microscopy of smears and sections from lesions. Trans R Soc Trop Med Hyg 1996; 90:133–135.

    Article  PubMed  CAS  Google Scholar 

  32. Vianna G. Tratamento da leishmaniose tegumentar por injecções intravenosas de Tartaro emetico. Ann 7 o Congr Bras Med Cirurg 1912; 4:426–428.

    Google Scholar 

  33. Roberts WL, Rainey PM. Antileishmanial activity of sodium stibogluconate fractions. Antimicrob Agents Chemother 1993; 37:1842–1846.

    PubMed  CAS  Google Scholar 

  34. Berman JD, Gallalée JF, Gallalée JV. Pharmacokinotics of pentavalent antimony (Pentostam) in hamsters. Am J Trop Med Hyg 1988; 39:41–45.

    PubMed  CAS  Google Scholar 

  35. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46:296–306.

    PubMed  CAS  Google Scholar 

  36. Hadighi R, Mohebali M, Boucher P et al. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drugresistant Leishmania tropica parasites. PLoS Med 2006; 3:e162.

    Article  PubMed  CAS  Google Scholar 

  37. Thakur CP, Sinha GP, Barat D, Singh RK. Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis ? Ann Trop Med Parasitol 1994; 88:365–370.

    PubMed  CAS  Google Scholar 

  38. Davidson RN, Croft SL, Scott A et al. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 1991; 337:1061–1062.

    Article  PubMed  CAS  Google Scholar 

  39. Brown M, Noursadeghi M, Boyle J, Davidson RN. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 2005; 153:203–205.

    Article  PubMed  CAS  Google Scholar 

  40. Olliaro PL, Guerin PJ, Gerstl S et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis 2005; 5:763–774.

    Article  PubMed  Google Scholar 

  41. Pradinaud R, Servan G, Sainte-Marie D et al. Bilan de 10 années de traitement de la leishmaniose tégumentaire par la pentamidine en Guyane française: à propos de 1 025 cas. Nouv Dermatol 1991; 10:456.

    Google Scholar 

  42. Sand M, Kron MA, Brown R. Pentamidine, a review. Rev Inf Dis 1985; 7:625–634.

    Google Scholar 

  43. Roussel M, Nacher M, Fremont G et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2006; 100:307–314.

    Article  PubMed  CAS  Google Scholar 

  44. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans Roy Soc Trop Med Hyg 1990; 84:221–225.

    Article  PubMed  CAS  Google Scholar 

  45. Thakur CP, Olliaro P, Gothoskar S et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combination, a pilot study in Bihar, India. Trans Roy Soc Trop Med Hyg 1992; 86:615–616.

    Article  PubMed  CAS  Google Scholar 

  46. Hepburn NC, Tidman MJ, Hunter JAA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans Roy Soc Trop Med Hyg 1994; 88:700–703.

    Article  PubMed  CAS  Google Scholar 

  47. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as singleagent therapy for Colombian cutaneous leishmaniasis. Trans Roy Soc Trop Med Hyg 1994; 88:695–698.

    Article  PubMed  CAS  Google Scholar 

  48. El-On J, Livshin R, Even-Paz Z et al. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986; 87:284–288.

    Article  PubMed  CAS  Google Scholar 

  49. Bryceson ADM, Murphy A, Moody AH. Treatment of « Old World » cutaneous leishmaniasis with aminosidine oinment: results of an open study in London. Trans Roy Soc Trop Med Hyg 1994; 88:226–228.

    Article  PubMed  CAS  Google Scholar 

  50. Asilian A, Jalayer T, Whitworth JA et al. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995; 53:648–651.

    PubMed  CAS  Google Scholar 

  51. Ben Salah A, Zakraoui H, Zaatour A et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995; 53:162–166.

    PubMed  CAS  Google Scholar 

  52. Asilian A, Jalayer T, Nilforooshzadeh M et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003; 81:353–359.

    PubMed  CAS  Google Scholar 

  53. Soto JM, Toledo JT, Gutierrez P et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002; 66:147–151.

    PubMed  CAS  Google Scholar 

  54. Ben Salah A, Buffet PA, Louzir H et al. (2005) WR279396 an efficient non toxic topical treatment of old world cutaneous leishmaniosis. Abstracts IIIrd World Congress on leishmaniosis, Palermo (Italy) 2005: 17.

    Google Scholar 

  55. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. New England J Med 1992; 326:741–744.

    CAS  Google Scholar 

  56. Velez I, Agudelo S, Hendrickx E et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trail. Ann Intern Med 1997; 126:232–236.

    PubMed  CAS  Google Scholar 

  57. Navin TR, Arana BA, Arana FE et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528–534.

    PubMed  CAS  Google Scholar 

  58. Dedet JP, Jamet P, Esterre P et al. Failure to cure Leishmania braziliensis guyanensis cutaneous leishmaniasis with oral ketoconazole. Trans Roy Soc Trop Med Hyg 1986; 80:176.

    Article  PubMed  CAS  Google Scholar 

  59. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of Pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16:417–425.

    PubMed  CAS  Google Scholar 

  60. Dogra J, Aneja N, Behari B, Mishra SN. Cutaneous leishmaniasis in India. Clinical experience with itraconazole (R51 211 Janssen). Int J Dermatol 1990; 29:661–662.

    Article  PubMed  CAS  Google Scholar 

  61. Momeni AZ, Jalayer T, Emamjomeh M et al. Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Arch Dermatol 1996; 132:784–786.

    Article  PubMed  CAS  Google Scholar 

  62. Alrajhi AA, Ibrahim EA, De Vol EB et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891–895.

    Article  PubMed  CAS  Google Scholar 

  63. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemther 1992; 36:1630–1634.

    CAS  Google Scholar 

  64. Olliaro PL, Guerin PJ, Gerstl S et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis 2005; 5:763–774.

    Article  PubMed  Google Scholar 

  65. Soto J, Arana BA, Toledo J et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266–1272.

    Article  PubMed  CAS  Google Scholar 

  66. Soto J, Toledo J, Gutierrez P et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:E57–61.

    Article  PubMed  CAS  Google Scholar 

  67. Murray HW, Berman JD, Wright SD. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J Inf Dis 1988; 157:973–978.

    CAS  Google Scholar 

  68. Badaro R, Falcoff E, Badaro FS et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. New Engl J Med 1990; 322:16–21.

    Article  PubMed  CAS  Google Scholar 

  69. Squires KE, Rosenkaimer F, Sherwood JA et al. Immunochemotherapy for visceral leishmaniasis is a controlled pilot trial of antimony versus antimony plus interferon-gamma. Amer J Trop Med Hyg 1993; 48:666–669.

    CAS  Google Scholar 

  70. Falcoff E, Taranto NJ, Remondegui CE et al. Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-γ and pentavalent antimonial compounds. Trans Roy Soc Trop Med Hyg 1993; 88:95–97.

    Article  Google Scholar 

  71. Buates S, Matlashewski G. Treatment of experimental leishmaniasiswith the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179:1485–1494.

    Article  PubMed  CAS  Google Scholar 

  72. Seeberger J, Daoud S, Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol 2003; 42:576–579.

    Article  PubMed  CAS  Google Scholar 

  73. Miranda-Verastegui C, Llanos-Cuentas A, Arevalo I et al. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005; 40:1395–1403.

    Article  PubMed  CAS  Google Scholar 

  74. Belazzoug S, Neal R. Failure of meglumine antimoniate to cure cutaneous leishmaniasis due to Leishmania major in Algeria. Trans R Soc Trop Med Hyg 1986; 80:670–671.

    Article  PubMed  CAS  Google Scholar 

  75. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994; 50:107–111.

    PubMed  CAS  Google Scholar 

  76. Teklemariam S, Hiwot AG, Frommel D et al. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans Roy Soc Trop Med Hyg 1994; 88:334–339.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Parasitologie et de Mycologie, Centre national de référence des Leishmania, Centre collaborateur OMS sur les leishmanioses, CHU de Montpellier et Université Montpellier 1, 163 rue Auguste-Broussonnet, 34090, Montpellier

    Jean-Pierre Dedet (Professeur des Universités et Praticien hospitalier)

Authors
  1. Jean-Pierre Dedet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Dedet, JP. (2008). Leishmanioses cutanées. In: Manifestations dermatologiques des maladies infectieuses, métaboliques et toxiques. Springer, Paris. https://doi.org/10.1007/978-2-287-48494-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-48494-0_18

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-48493-3

  • Online ISBN: 978-2-287-48494-0

Publish with us

Policies and ethics

Search

Navigation